OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
In 2021, Takeda announced a partnership with Novavax to manufacture 150 million doses of the Nuvaxovid COVID-19 vaccine; however, the Japanese government has canceled its order for the remaining 141.76 million doses due to low demand.
Japan's cancellation of the Novavax vaccine order will not significantly impact Takeda's finances and the company is not altering its full-year consolidated forecasts.
Related Content: